Ovarian cancer: a new blood test for early diagnosis
A molecular ‘marker’ capable of detecting precancerous lesions that escape detection by traditional tests has been identified. The findings, published in *Nature Medicine*, open up new prospects for early diagnosis. However, the test has yet to be validated.
Key points
Detecting an ovarian tumour whilst it is still at an early stage, before it has become invasive, is one of the major challenges in oncology. Ovarian tumours, for example, develop without causing any recognisable symptoms and are therefore often diagnosed when the disease is already at an advanced stage, as there are no screening tests available. However, new research published in Nature Medicine suggests that one of the most aggressive forms of ovarian cancer may release valuable clues into the bloodstream, long before it can be detected using currently available imaging techniques and tumour markers.
The ‘message in a bottle’ from a tumour in the blood, even at an early stage
The potential breakthrough comes from a molecule called Tu-stroma, a sort of ‘message in a bottle’ that circulates in the blood within tiny vesicles released by cells. Researchers have discovered that this signal may already be present in precancerous lesions of the fallopian tubes, from which high-grade serous carcinoma – one of the most aggressive forms of ovarian cancer – can develop. The study analysed blood samples from 506 women; of these, 43 had precancerous lesions, 232 had high-grade serous carcinoma, 88 had benign adnexal masses and 143 were tumour-free controls. The samples were divided into a group used to develop the test and another, independent group to assess its performance (validation group).
The results of this study are very interesting. In the validation group, the new marker identified around 95 per cent of precancerous lesions and tumours diagnosed at an early stage. Even more interesting is the comparison with CA 125, the tumour marker routinely used in the clinical assessment of ovarian cancer, which, however, proves to be unreliable in the earliest stages.
Tu-stroma outperforms traditional tumour markers in terms of accuracy
When the researchers compared the ability of the two tests to distinguish precancerous lesions from women without cancer, Tu-stroma achieved a high diagnostic accuracy rate, significantly higher than that of CA 125, confirming that the new test has a markedly superior ability to distinguish between the two.
This difference is particularly significant because some precancerous lesions and early-stage tumours still had CA125 levels within the normal range, whilst the new marker was already elevated. Conversely, in several women with benign conditions that can cause an increase in CA125, Tu-stroma levels remained low.

